Research programme: tumour necrosis factor alpha inhibitors - Singh Biotechnology

Drug Profile

Research programme: tumour necrosis factor alpha inhibitors - Singh Biotechnology

Alternative Names: SBT 104

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Singh Biotechnology
  • Class Anti-inflammatories; Antipsoriatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psoriasis
  • Research Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 17 Oct 2017 Preclinical trials in Psoriasis in USA before October 2017 (Singh Biotechnology pipeline, October 2017)
  • 04 Aug 2016 Singh Biotechnology has patent protection for tumour necrosis factor alpha inhibitors (Singh Biotechnology website, August 2016)
  • 01 Dec 2015 Early research is underway for Rheumatoid arthritis and inflammatory bowel disease in the US (Singh Biotechnology website, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top